Skip to content
  • Home
  • About Us
        • About APLAR
          • APLAR Milestones
          • President Message
        • Committees
          • APLAR Directors
          • Executive Committee
          • Other Committees
        • Membership
          • Member National Organizations
          • Constitution & Terms of Reference
          • Membership Application
          • Membership Update
  • Academy
        • APLAR Academy
          • Governance
          • Membership
        • Short Course
          • Upcoming Course
          • Past Course
        • Academy Webinar
          • Upcoming Webinar
          • Past Webinar
        • Grand Round
          • Upcoming Grand Round
          • Past Grand Round
          • Discussion Forum
          • Grand Round Blackboard
        • ASPIRE Grant
          • About APLAR ASPIRE
          • ASPIRE Core Training Modules
          • ASPIRE Implementation Toolkit
  • About SIG
  • AYR
        • ABOUT AYR
          • AYR Board
          • Committee
          • AYR Membership
        • AYR Webinar
          • Upcoming Webinar
          • Past Webinar
          • AYR Blackboard
          • Discussion Forum
  • Collaboration
        • APLAR ESOR
          • ESOR Application
          • Post Event Submission
          • Online Submission
          • EULAR School of Rheumatology
        • Exchange Programme
          • Exchange Programe Application
          • Online Submission
          • EULAR Exchange Program
        • APLAR MNO Patronage
          • Patronage Application
          • Online Submission
          • EULAR Collaborations
        • Center Of Excellence
          • APLAR CoEs
          • New Application
          • Renew CoE Application
          • Online Submission
  • Grants and Awards
        • Grant
          • COPCORD Grant
          • Congress Travel Grant
          • Research Grant
          • Fellowship Grant
        • Award
          • Master Award
  • Events
        • Congress
          • Upcoming Congress
          • Past Congress
        • Events
          • Upcoming Events
          • Past Events
        • Gallery
  • Publications
        • Published Journal
          • SIG Publication
          • COVID – 19 Publication
        • IJRD
        • Voice Of APLAR
  • Patient Education

AYR 1st Webinar Blackboard 2022

Step 1 of 3

33%
  • QUESTION 1

    A 50-year old Chinese lady comes to your office with a Raynaud s phenomenon existing since ten years. She is a teacher, she has a negative medical history. She has no other rheumatological or internal medicine complaints. A capillaroscopy is being performed in the investigation of the Raynauds phenomenon.


  • Your Answer is Incorrect

    Answer with Detailed explanation

    The correct answer is This is a scleroderma pattern according to the Fast track algorithm

    The Fast track algorithm (Smith V. et al. Autoimmun Rev. 2019 Nov;18(11):102394.) consists of three rules. More specifically rule number 1: when the density of an image is 7 or more and there are no giants, then you have a non scleroderma pattern. Rule number 2: when you have giants, or an extremely lowered density (3 or less capillaries in a linear mm) consisting of abnormal shapes then you have a scleroderma pattern. Rule number 3: all pictures who don’t belong to rule 1 or rule 2 can be automatically classified as rule 3, which is: a non scleroderma pattern. The picture shown here belongs under rule number 3 and is subsequently not a scleroderma pattern.

    By
    Prof Maurizio Cutolo
    Professor of Rheumatology and Professor of Internal Medicine,
    Director of Laboratories for Experimental Rheumatology and Academic Division of Clinical Rheumatology
    Director of Postgraduate School of Rheumatology
    University of Genova, Italy

    Prof Vanessa Smith
    Head of Clinics, Ghent University Hospital
    Associate Professor of Rheumatology
    Ghent University, Belgium


  • Your Answer is Correct

    Answer with Detailed explanation

    The Fast track algorithm (Smith V. et al. Autoimmun Rev. 2019 Nov;18(11):102394.) consists of three rules. More specifically rule number 1: when the density of an image is 7 or more and there are no giants, then you have a non scleroderma pattern. Rule number 2: when you have giants, or an extremely lowered density (3 or less capillaries in a linear mm) consisting of abnormal shapes then you have a scleroderma pattern. Rule number 3: all pictures who don’t belong to rule 1 or rule 2 can be automatically classified as rule 3, which is: a non scleroderma pattern. The picture shown here belongs under rule number 3 and is subsequently not a scleroderma pattern.

    By
    Prof Maurizio Cutolo
    Professor of Rheumatology and Professor of Internal Medicine,
    Director of Laboratories for Experimental Rheumatology and Academic Division of Clinical Rheumatology
    Director of Postgraduate School of Rheumatology
    University of Genova, Italy

    Prof Vanessa Smith
    Head of Clinics, Ghent University Hospital
    Associate Professor of Rheumatology
    Ghent University, Belgium

  • QUESTION 2

    Concerning this 50-year old Chinese, with a Raynaud s phenomenon existing since ten years and a negative medical history.


  • Your Answer is Incorrect

    Answer with Detailed explanation

    The correct answer is
    B. When she has no scleroderma pattern on capillaroscopy and no SSc specific antibodies then her chance to get systemic sclerosis is less than 10% over the long run according to the landmark study of Koenig et al.
    D. When she has no scleroderma pattern on capillaroscopy and an anti -centromere then she has less than 30 % to develop systemic sclerosis according to Koenig et al in the long run
    E. When she both has a scleroderma pattern and an SSc specific antibody then she has a high chance to get systemic sclerosis.

    Explanation concerning A,B and E: The landmark study of Koenig et al. (Arthritis Rheum. 2008 Dec;58(12):3902-12.) nicely showed that in a patient population the Raynauds phenomenon at baseline but no other signal of a connective tissue disease that patients who have no SSc-specific antibody and no scleroderma pattern on capillaroscopy have a very low chance (1.8% over the long run) to develop SSc (table 4 in the manuscript by Koenig et al.)
    Hence A was not correct.
    Hence B was correct.

    Explanation concerning E: Conversely Koeing et al showed that those with both SSc-specific antibodies (Anti–topo I , anti–RNAP III and Anti–CENP-B) and a scleroderma pattern on capillaroscopy do have very high chance to get systemic sclerosis over de long run, more specifically 79,5%.
    Hence E is correct.

    Explanation concerning C: anti SSa is not a systemic sclerosis antibody hence this patient does not have a high chance. In fact, the landmark study of Koenig et al. (Arthritis Rheum. 2008 Dec;58(12):3902-12.) nicely showed that in a patient population the Raynauds phenomenon at baseline but no other signal of a connective tissue disease that patients who have no SSc-specific antibody and no scleroderma pattern on capillaroscopy have a very low chance (1.8% over the long run) to develop SSc (table 4 in the manuscript by Koenig et al.)

    Explanation concerning D: If there is no scleroderma pattern but only an SSc specific antibody positivity then the landmark paper of Koenig show that the chance to develop SSc is only 23% over the long run.
    Hence it is correct to say that the chance is less than 30%.

    By
    Prof Maurizio Cutolo
    Professor of Rheumatology and Professor of Internal Medicine,
    Director of Laboratories for Experimental Rheumatology and Academic Division of Clinical Rheumatology
    Director of Postgraduate School of Rheumatology
    University of Genova, Italy

    Prof Vanessa Smith
    Head of Clinics, Ghent University Hospital
    Associate Professor of Rheumatology
    Ghent University, Belgium


  • Your Answer is Correct

    Answer with Detailed explanation

    Explanation concerning A,B and E: The landmark study of Koenig et al. (Arthritis Rheum. 2008 Dec;58(12):3902-12.) nicely showed that in a patient population the Raynauds phenomenon at baseline but no other signal of a connective tissue disease that patients who have no SSc-specific antibody and no scleroderma pattern on capillaroscopy have a very low chance (1.8% over the long run) to develop SSc (table 4 in the manuscript by Koenig et al.)
    Hence A was not correct.
    Hence B was correct.

    Explanation concerning E: Conversely Koeing et al showed that those with both SSc-specific antibodies (Anti–topo I , anti–RNAP III and Anti–CENP-B) and a scleroderma pattern on capillaroscopy do have very high chance to get systemic sclerosis over de long run, more specifically 79,5%.
    Hence E is correct.

    Explanation concerning C: anti SSa is not a systemic sclerosis antibody hence this patient does not have a high chance. In fact, the landmark study of Koenig et al. (Arthritis Rheum. 2008 Dec;58(12):3902-12.) nicely showed that in a patient population the Raynauds phenomenon at baseline but no other signal of a connective tissue disease that patients who have no SSc-specific antibody and no scleroderma pattern on capillaroscopy have a very low chance (1.8% over the long run) to develop SSc (table 4 in the manuscript by Koenig et al.)

    Explanation concerning D: If there is no scleroderma pattern but only an SSc specific antibody positivity then the landmark paper of Koenig show that the chance to develop SSc is only 23% over the long run.
    Hence it is correct to say that the chance is less than 30%.

    By
    Prof Maurizio Cutolo
    Professor of Rheumatology and Professor of Internal Medicine,
    Director of Laboratories for Experimental Rheumatology and Academic Division of Clinical Rheumatology
    Director of Postgraduate School of Rheumatology
    University of Genova, Italy

    Prof Vanessa Smith
    Head of Clinics, Ghent University Hospital
    Associate Professor of Rheumatology
    Ghent University, Belgium

  • Address: 1 Scotts Road #24-10 Shaw Center Singapore 228208
  • Email: secretariat@aplar.org

Social Media

Subscribe

By providing email, I agree to receive all corespondances from APLAR

ALL RIGHTS RESERVED © 2023 | APLAR.ORG